Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laser Medical Technology

This article was originally published in The Gray Sheet

Executive Summary

Eurocapital Ltd. places 1,209,000 shares of firm's stock, formerly owned by company founder Guy Levy and his son Francois Levy, "into the hands of long-term investors." The transaction, which severs "all working relationship with the Levy family," is significant "because Dr. Levy and his sons have been the only important suppliers of stock in the marketplace, particularly in the past few months," Laser Medical says. As a condition of the placement, Eurocapital asked Dr. Levy to sell back to the company his patent royalty agreement expiring in 2010, valued at $84,000 a year plus cost of living adjustment, in exchange for a one time payment of $100,000. Dr. Levy received "50,000 shares with certain restrictions, and an option to buy three lasers at the current distributor price" as part of the transaction. The firm said the deal will result in an extraordinary gain of more than $400,000 for the first quarter ending in March.

You may also be interested in...



Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel